Literature DB >> 7388738

A mass screening program for colorectal cancer using chemical testing for occult blood in the stool.

D P Winchester, J H Shull, E F Scanlon, J V Murrell, C Smeltzer, P Vrba, M Iden, D H Streelman, R Magpayo, J W Dow, J Sylvester.   

Abstract

Following five promotional and educational programs on CBS-TV news in Chicago, 54,101 Hemoccult kits were requested by the public and distributed by seven cancer detection facilities. Only 14,074 individuals completed the test. Six hundred and seventeen or 4.38% were positive. Two hundred and fifteen test positive persons failed to respond to repeated notification. In 123 positives, diagnostic tests by the private physician were considered incomplete. In 33 positives, the private physician did no further testing at all. In 152 positives, no abnormality could be found, but work-up was variable. One hundred and eighty-seven had abnormalities other than cancer, including 40 with polyps. Twenty-seven asymptomatic and two symptomatic cancers were found. Nearly two-thirds had Dukes A or B lesions, while one-third had Dukes C tumors. Public compliance in both completing kits and following through with positive results was low. Physician evaluation of positives was often incomplete. Chemical testing for occult fecal blood, when properly combined with other tests such as proctoscopy, has the potential for lowering mortality from colorectal cancer. Continued public and professional education is needed.

Entities:  

Mesh:

Year:  1980        PMID: 7388738     DOI: 10.1002/1097-0142(19800615)45:12<2955::aid-cncr2820451211>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Occult blood testing for early detection of colorectal cancer: diagnostic outcomes.

Authors:  T G Hislop; B J Morrison; P E Hoogewerf; S D Burns; R Sizto
Journal:  Can Fam Physician       Date:  1987-12       Impact factor: 3.275

2.  Screening for carcinoma of the colon: a family practice perspective.

Authors:  J F Sangster; T M Gerace
Journal:  Can Fam Physician       Date:  1982-09       Impact factor: 3.275

3.  Early detection of colon cancer-the kaiser permanente northwest 30-year history: how do we measure success? Is it the test, the number of tests, the stage, or the percentage of screen-detected patients?

Authors:  David Moiel; John Thompson
Journal:  Perm J       Date:  2011

4.  Detecting colorectal cancer with a large scale fecal occult blood testing program.

Authors:  D I Gregorio; P Lolachi; H Hansen
Journal:  Public Health Rep       Date:  1992 May-Jun       Impact factor: 2.792

5.  Symposium: Screening for colorectal cancer.

Authors:  F Macrae; G Ekelund; B P Robra; R Gnauck; H Ribet; J Escourrou; J H Bond; N C Armitage; J B Simon
Journal:  Int J Colorectal Dis       Date:  1986-04       Impact factor: 2.571

6.  Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing.

Authors:  Charlene L Stokamer; Craig T Tenner; Jhuma Chaudhuri; Eva Vazquez; Edmund J Bini
Journal:  J Gen Intern Med       Date:  2005-03       Impact factor: 5.128

7.  Family physicians' beliefs about screening for colorectal cancer using the stool guaiac slide test.

Authors:  K M Cummings; C R Jaen; D P Funch
Journal:  Public Health Rep       Date:  1984 May-Jun       Impact factor: 2.792

8.  Colorectal screening by a self-completion questionnaire.

Authors:  P A Farrands; J D Hardcastle
Journal:  Gut       Date:  1984-05       Impact factor: 23.059

9.  Screening for colorectal neoplasia: physicians' adherence to complete diagnostic evaluation.

Authors:  R E Myers; A M Balshem; T A Wolf; E A Ross; L Millner
Journal:  Am J Public Health       Date:  1993-11       Impact factor: 9.308

10.  Improving fecal occult blood testing compliance using a mailed educational reminder.

Authors:  Jeffrey K Lee; Veronica Reis; Shanglei Liu; Lorraine Conn; Erik J Groessl; Theodore G Ganiats; Samuel B Ho
Journal:  J Gen Intern Med       Date:  2009-09-23       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.